Search results for "BONE-MARROW"

showing 10 items of 11 documents

Extinct type of human parvovirus B19 persists in tonsillar B cells

2017

Parvovirus B19 (B19V) DNA persists lifelong in human tissues, but the cell type harbouring it remains unclear. We here explore B19V DNA distribution in B, T and monocyte cell lineages of recently excised tonsillar tissues from 77 individuals with an age range of 2–69 years. We show that B19V DNA is most frequent and abundant among B cells, and within them we find a B19V genotype that vanished from circulation >40 years ago. Since re-infection or re-activation are unlikely with this virus type, this finding supports the maintenance of pathogen-specific humoral immune responses as a consequence of B-cell long-term survival rather than continuous replenishment of the memory pool. Moreover, we …

0301 basic medicineSYNOVIAL TISSUEvirusesPalatine TonsilGeneral Physics and AstronomyAntibodies ViralGenotypeINFECTIONParvovirus B19 HumanREAL-TIME PCRChildCells CulturedB-LymphocytesMultidisciplinarybiologyQcell type harbouringvirus diseasesU937 CellsMiddle Aged3. Good healthHUMAN ERYTHROVIRUSESsolutReal-time polymerase chain reactionmedicine.anatomical_structurePLASMA-CELLSChild PreschoolGENETIC DIVERSITYAntibodyAdultCell typeAdolescentGenotypeBONE-MARROWScience030106 microbiologyQUANTITATIVE PCRta3111ArticleGeneral Biochemistry Genetics and Molecular BiologyCell LineParvoviridae InfectionsYoung Adult03 medical and health sciencesImmune systemCell Line TumormedicineHumansAgedB cellsparvovirus B19ParvovirusMonocyteta1182General ChemistryDNAvirus typesbiology.organism_classificationVirologyCELLULAR CORECEPTOR030104 developmental biologyCell cultureDNA ViralImmunologybiology.proteincells3111 BiomedicineNature Communications
researchProduct

The mycotoxin zearalenone enhances cell proliferation, colony formation and promotes cell migration in the human colon carcinoma cell line HCT116.

2016

IF 3.522; International audience; Zearalenone (ZEN) and Aflatoxin B1 (AFB1) are fungal secondary metabolites produced by Fusarium and Aspergillus genera, respectively. These mycotoxins are found world-wide as corn and wheat contaminants. AFB1 is probably the most toxic and carcinogenic mycotoxin. It has been demonstrated to be mutagenic, genotoxic, and hepatocarcinogenic. ZEN is a non-steroidal estrogenic mycotoxin that displays hepatotoxicity, immunotoxicity and genotoxicity. Its mutagenic and carcinogenic properties have so far remained controversial and questionable. Using the colon carcinoma cell line HCT116, we will show here that ZEN, at low concentrations, enhances cell proliferation…

0301 basic medicineBone-Marrow-CellsAflatoxinAflatoxin B1Time Factors[ SDV.TOX ] Life Sciences [q-bio]/ToxicologyToxicologymedicine.disease_causeInductionchemistry.chemical_compound0302 clinical medicineProliferation assayCell MovementZearalenonebiologyfood and beveragesCell migrationGeneral MedicineMigration assayDna-Damage030220 oncology & carcinogenesis[SDV.TOX]Life Sciences [q-bio]/ToxicologyColonic NeoplasmsZearalenoneChromosome-AberrationsBalb/C MiceFusariumendocrine systemPreventive Role03 medical and health sciencesBotanymedicineHumansNeoplasm InvasivenessMycotoxinCarcinogenCell ProliferationWound HealingDose-Response Relationship DrugCell growthfungiClonogenic assaybiology.organism_classificationHCT116 CellsMolecular biology030104 developmental biologychemistryMcf-7 CellsFusarium ToxinsIn-VitroVitamin-ECarcinogensGenotoxicityToxicology letters
researchProduct

Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosis

2006

Familial haemophagocytic lymphohistiocytosis (FHL) is a genetically heterogeneous disorder characterised by constitutive defects in cellular cytotoxicity resulting in fever, hepatosplenomegaly and cytopenia, and the outcome is fatal unless treated by chemoimmunotherapy followed by haematopoietic stem‐cell transplantation. Since 1999, mutations in the perforin gene giving rise to this disease have been identified; however, these account only for 40% of cases. Lack of a genetic marker hampers the diagnosis, suitability for transplantation, selection of familial donors, identification of carriers, genetic counselling and prenatal diagnosis. Mutations in the Munc13–4 gene have recently been des…

EXPRESSIONMalePRF1AdolescentFHLBlotting WesternDNA Mutational AnalysisHepatosplenomegalyDONORSPrenatal diagnosisBiologymedicine.disease_causeLymphohistiocytosis HemophagocyticGeneticsmedicinePERFORIN GENE-MUTATIONSHumansUNC13DChildGenetics (clinical)Family HealthSPECTRUMHemophagocytic lymphohistiocytosisMutationCytopeniaMicroscopy ConfocalIDENTIFICATIONGenetic heterogeneityInfant NewbornCYTOTOXIC T-LYMPHOCYTESInfantMembrane Proteinsmedicine.diseaseBONE-MARROW-TRANSPLANTATIONTransplantationMicroscopy ElectronChild PreschoolMutationImmunologyFemalemedicine.symptomLetter to JMGT-Lymphocytes CytotoxicJournal of Medical Genetics
researchProduct

An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients.

2009

OBJECTIVES: Caspofungin was evaluated as first-line monotherapy of invasive aspergillosis (IA) in patients with haematological malignancies and undergoing autologous transplants. METHODS: Adults with proven or probable IA, defined strictly according to EORTC-MSG criteria, were eligible. Those with possible IA were enrolled, but were not evaluable for efficacy unless upgraded to proven/probable disease within 7 days of registration based on investigations performed within 48 h after enrolment. Caspofungin dosage was 70 mg (day 1) followed by 50 mg/day. The primary endpoint was the proportion of patients with complete or partial response at the end of caspofungin therapy in the modified inten…

Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsNeutropeniaAspergillosisGastroenterologyTransplantation Autologouschemistry.chemical_compoundEchinocandinsLipopeptidesYoung AdultCaspofunginInternal medicineClinical endpointmedicineAspergillosisHumansPharmacology (medical)Survival rateSurvival analysisAgedPharmacologyAged 80 and overSurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryTransplantationAcute Leukaemia; Fungal Infections; Echinocandins; Bone-Marrow-Transplantation; Stem-Cell Transplants; Mycoses Study-Group; Fungal-Infections; Prognostic-Factors; European-Organization; Amphotericin-B; Consensus; Epidemiology; VoriconazoleInfectious DiseasesTreatment OutcomechemistryHematologic NeoplasmsFemaleCaspofunginbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Splenic marginal zone lymphoma: A prognostic model for clinical use

2006

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence …

Malesplenic marginal zone lymphoma; prognostic factors; International Prognostic Index (IPI)VILLOUS LYMPHOCYTESHydro-LyaseB-CELLLongitudinal StudiePredictive Value of TestInternational Prognostic Index (IPI)BiochemistryGastroenterologyHemoglobinschemistry.chemical_compoundInternational Prognostic IndexRisk FactorsBONE-MARROW INFILTRATION; NON-HODGKINS-LYMPHOMA; C VIRUS-INFECTION; VILLOUS LYMPHOCYTES; B-CELLBONE-MARROW INFILTRATIONAge FactorLongitudinal StudiesMultivariate AnalysiAged 80 and overUnivariate analysisHematologyMortality rateAge FactorsHematologyMiddle AgedPrognosisSplenic NeoplasmSurvival RatePredictive value of testsHumanAdultmedicine.medical_specialtyLymphoma B-CellPrognosiImmunologysplenic marginal zone lymphomaDisease-Free SurvivalPredictive Value of TestsAlbuminsInternal medicineLactate dehydrogenaseAdult; Age Factors; Aged; Aged 80 and over; Albumins; Disease-Free Survival; Hemoglobins; Humans; Hydro-Lyases; Longitudinal Studies; Lymphoma B-Cell; Male; Middle Aged; Multivariate Analysis; Platelet Count; Predictive Value of Tests; Prognosis; Risk Factors; Splenic Neoplasms; Survival Rate; Models Theoretical; HematologymedicineHumansHemoglobinNON-HODGKINS-LYMPHOMASplenic marginal zone lymphomaSurvival rateHydro-LyasesAgedPlatelet Countbusiness.industrySplenic NeoplasmsAlbuminRisk Factorprognostic factorsCell BiologyModels Theoreticalmedicine.diseaseSurgerychemistryMultivariate AnalysisbusinessC VIRUS-INFECTION
researchProduct

The HSP90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development.

2016

IF 7.932; International audience; Graft versus host disease (GvHD), which is the primary complication of allogeneic bone marrow transplantation, can alter the intestinal barrier targeted by activated donor T-cells. Chemical inhibition of the stress protein HSP90 was demonstrated in vitro to inhibit T-cell activation and to modulate endoplasmic reticulum (ER) stress to which intestinal cells are highly susceptible. Since the HSP90 inhibitor 17-allylamino-demethoxygeldanamycin (17AAG) is developed in clinics, we explored here its ability to control intestinal acute GvHD in vivo in two mouse GvHD models (C57BL/6 -> BALB/c and FVB/N -> Lgr5-eGFP), ex vivo in intestine organoids and in vitro in …

0301 basic medicineX-Box Binding Protein 1Cancer ResearchLactams MacrocyclicRNA SplicingT-CellsGraft vs Host Disease[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiology[ SDV.CAN ] Life Sciences [q-bio]/CancerHsp90 inhibitor03 medical and health sciencesMiceSensitivityInflammatory-Bowel-diseaseGeneticsmedicineBenzoquinonesAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyNeural progenitor cellsHSP90 Heat-Shock ProteinsIntestinal MucosaStem Cell Niche[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human genetics[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular BiologyLeukemia[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyBone-Marrow-TransplantationMoleculesmedicine.diseaseStem cell niche3. Good healthIre1-AlphaIntestinesMice Inbred C57BL030104 developmental biologyGraft-versus-host diseaseEr Stress[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsCytoprotectionImmunologyMultiple-MyelomaFemaleOncogene
researchProduct

Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplan…

2004

International audience; Background. Isolated case reports have shown that recipients of allogeneic hematopoietic stem cell transplants ( HSCTs) who develop toxoplasmosis may have circulating Toxoplasma gondii DNA in peripheral blood before the onset of clinical symptoms. Methods. We prospectively studied 106 T. gondii - seropositive adult recipients of HSCTs for the incidence of reactivation of toxoplasmosis in the first 6 months after transplantation. Toxoplasmosis infection ( TI) was defined by a positive result of polymerase chain reaction ( PCR) of peripheral blood specimens, whereas toxoplasmosis disease ( TD) was defined as an invasive infection. Results. The incidence of TI was 16% (…

AdultMicrobiology (medical)POLYMERASE-CHAIN-REACTIONmedicine.medical_treatment[SDV]Life Sciences [q-bio]Hematopoietic stem cell transplantationPolymerase Chain ReactionParasite loadCYTOMEGALOVIRUS-INFECTIONBlood cell03 medical and health sciencesIMMUNE RECONSTITUTION0302 clinical medicinemedicineAnimalsHumansTransplantation Homologous030212 general & internal medicineREAL-TIME PCR0303 health sciencesHematologic Testsbiology030306 microbiologybusiness.industryIncidence (epidemiology)Toxoplasma gondiiDNA Protozoanbiology.organism_classificationmedicine.diseaseBONE-MARROW-TRANSPLANTATIONPREEMPTIVE THERAPYToxoplasmosis3. Good healthTransplantationRECIPIENTSInfectious DiseasesReal-time polymerase chain reactionmedicine.anatomical_structureImmunologySTATISTICAL-METHODSTRANSFER HYBRIDIZATION PROBESbusinessToxoplasmaToxoplasmosisStem Cell Transplantation
researchProduct

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …

MDD0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisIMPACTBONE-MARROWFEATURESCHILDRENlong-term follow-uplcsh:RC254-282ArticleDISEASECLASSIFICATIONChildhood Anaplastic Large Cell Lymphoma03 medical and health sciences0302 clinical medicineInternal medicineADOLESCENTSmedicineVINBLASTINEProgression-free survivalYoung adultPathologicalAnaplastic large-cell lymphomachildhoodScience & Technologybusiness.industryHazard ratioCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCLALCL; MDD; childhood; long-term follow-up030104 developmental biologyOncology030220 oncology & carcinogenesisMinimal Disseminated DiseaseNON-HODGKIN-LYMPHOMAbusinessLife Sciences & BiomedicineCancers
researchProduct

Heart valve tissue engineering: how far is the bedside from the bench?

2015

Heart disease, including valve pathologies, is the leading cause of death worldwide. Despite the progress made thanks to improving transplantation techniques, a perfect valve substitute has not yet been developed: once a diseased valve is replaced with current technologies, the newly implanted valve still needs to be changed some time in the future. This situation is particularly dramatic in the case of children and young adults, because of the necessity of valve growth during the patient's life. Our review focuses on the current status of heart valve (HV) therapy and the challenges that must be solved in the development of new approaches based on tissue engineering. Scientists and physicia…

Aortic valveHeart diseaseSwine030204 cardiovascular system & hematology0302 clinical medicineHeart valve tissue engineeringHyaluronic AcidChildProsthetic valve0303 health sciencesMARROW-DERIVED CELLSTissue ScaffoldsFetal BloodHeart Valves3. Good healthmedicine.anatomical_structureHeart Valve ProsthesisCardiologyMolecular MedicineCollagenmedicine.medical_specialtyPULMONARY VALVEBONE-MARROWInduced Pluripotent Stem CellsVENTRICULAR OUTFLOW TRACTMESENCHYMAL STEM-CELLS03 medical and health sciencesTissue scaffoldsInternal medicineEXTRACELLULAR-MATRIXmedicineAnimalsHumansHeart valveIntensive care medicineENDOTHELIAL PROGENITOR CELLSMolecular Biology030304 developmental biologyBioprosthesisAORTIC-VALVEFibrinSheepTissue Engineeringbusiness.industryEndothelial Cellsmedicine.diseaseTransplantationPulmonary valveUMBILICAL-CORD BLOOD1182 Biochemistry cell and molecular biologybusinessHUMAN AMNIOTIC-FLUIDExpert Reviews in Molecular Medicine
researchProduct

Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis.

2009

Aims: Essential thrombocythaemia (ET) and primary myelofibrosis (PMF) share some clinical and pathological features, but show different biological behaviour and prognosis. The latest contributions to understanding the nature of these disorders have focused on bone marrow microenvironment remodelling and proliferative stress, recognising megakaryocytes (MKCs) as “key-cells”. The aim of this study was to investigate the apoptotic profile of ET and PMF MKCs in order to further characterise the biology of these disorders. Methods: Bone marrow biopsy samples from 30 patients with ET, and 30 patients with PMF, were immunophenotypically studied for the expression of pro-apoptotic (Fas, Fas-L, Bax,…

AdultMalePathologymedicine.medical_specialtyBiopsyIDIOPATHIC MYELOFIBROSISApoptosisPOLYCYTHEMIA-VERASettore MED/08 - Anatomia PatologicaBiologyPathology and Forensic MedicineImmunophenotypingImmunophenotypingMegakaryocyteBone MarrowmedicineIn Situ Nick-End LabelingHumansTelomerase reverse transcriptaseMyelofibrosisMOLECULAR PERSPECTIVEAgedAged 80 and overTUNEL assayEssential thrombocythemiaC-MPLMUTATION STATUSGeneral MedicineMiddle Agedmedicine.diseasePrognosismedicine.anatomical_structureCHRONIC MYELOPROLIFERATIVE DISORDERSCELL-DEATHApoptosisPrimary MyelofibrosisRISK-FACTORSCancer researchBONE-MARROW ANGIOGENESISMYELOID METAPLASIAFemaleBone marrowMegakaryocytesThrombocythemia EssentialJournal of clinical pathology
researchProduct